The ITCC-059 phase Ib trial in pediatric patients with relapsed/refractory (R/R) CD22+ B-ALL evaluated InO in combination with vincristine, dexamethasone, and intrathecal therapy, yielding an ORR of 80% and a MRD negativity rate of 66.7%, with an established safety profile at 1.8 mg/m2 per cycle [16]. Here, CD22 is linked to acute lymphoblastic leukemia.